Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck

Pharmacogenetics and Genomics

Volumn 21, Issue 7, 2011, Pages 388-396

  Yu, Hongping ^a   Wang, Li E ^a   Liu, Zhensheng ^a   Wei, Sheng ^a   Li, Guojun ^a   Sturgis, Erich M ^a   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

case control; genetic susceptibility; head and neck neoplasms; MDM4 polymorphism; molecular epidemiology; oropharyngeal cancer

Indexed keywords

PROTEIN MDMX;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

HUMAN PAPILLOMAVIRUS;

EID: 79959806351     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834632e4     Document Type: Article

References (54)

1. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110:1429-1435. (Pubitemid 47463055)
2. Jemal A, Siegel R, Xu J,Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
3. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-475. (Pubitemid 40270113)
4. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92:709-720. (Pubitemid 30365531)
5. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001; 114: 4139-4140. (Pubitemid 33138651)
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310.
7. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505. (Pubitemid 23335075)
8. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1136. (Pubitemid 120035062)
9. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: .12. years and counting. Curr Cancer Drug Targets 2005; 5:3-8. (Pubitemid 40321795)
10. Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 2005; 331:750-760. (Pubitemid 40615506)
11. Toledo F,Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6:909-923. (Pubitemid 44862676)
12. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13:927-934.
13. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 1999; 274:38189-38196. (Pubitemid 30026893)
14. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999; 447:5-9. (Pubitemid 29134936)
15. Shvarts A, Bazuine M, Dekker P, Ramos YF, Steegenga WT, Merckx G, et al. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics 1997; 43:34-42. (Pubitemid 27310520)
16. Ried T, Just KE, Holtgreve-Grez H, du Manoir S, Speicher MR, Schrö ck E, et al. Comparative genomic hybridization of formalin-fixed, paraffinembedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 1995; 55:5415-5423.
17. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998; 21:177-184. (Pubitemid 28136434)
18. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004; 24: 5835-5843. (Pubitemid 38787968)
19. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001; 61:1839-1842. (Pubitemid 32691995)
20. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 2007; 38:1553-1562. (Pubitemid 47418967)
21. Bartel F, Schulz J, Blumke K, Kappler M, Bache M, Schmidt H, et al. HDMX amplification and high levels of HDMX-S splice variant are correlated with a poor prognosis in soft tissue sarcomas. Verh Dtsch Ges Pathol 2004; 88:199-206.
22. Bartel F, Schulz J, Bohnke A, Blümke K, Kappler M, Bache M, et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 2005; 117:469-475. (Pubitemid 41429571)
23. Sampieri K, Mencarelli MA, Epistolato MC, Toti P, Lazzi S, Bruttini M, et al. Genomic differences between retinoma and retinoblastoma. Acta Oncol 2008; 47:1483-1492.
24. Bai J, Dai J, Yu H, Shen H, Chen F. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J Toxicol Environ Health A 2009; 72:677-682.
25. Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 2010; 120: 211-216.
26. Fang F, Yu XJ, Yu L, Yao L. MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol .2010. [Epub ahead of print].
27. Gui XH, Qiu LX, Zhang HF, Zhang DP, Zhong WZ, Li J, et al. MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. Eur J Cancer 2009; 45:2023-2026.
28. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from .21. case-control studies. Cancer Epidemiol Biomarkers Prev 2007; 16:2717-2723. (Pubitemid 351196328)
29. Huang SF, Chen IH, Liao CT,Wang HM, Liou SH, Hsieh LL. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol 2009; 45:16-22.
30. Nakashima M, Kondo S, Shimizu Y, Wakisaka N, Murono S, Furukawa M, et al. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. Acta Otolaryngol 2008; 128:808-813. (Pubitemid 351882528)
31. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007; 28:2262-2267. (Pubitemid 350119563)
32. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010; 18:220-230.
33. Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R, et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci USA 2009; 106: 10236-10241.
34. Kulkarni DA, Vazquez A, Haffty BG, Bandera EV, Hu W, Sun YY, et al. A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis 2009; 30:1910-1915.
35. American Joint Committee on Cancer. Manual for staging of cancer. 4th ed. Philadelphia: J.B.Lippincott; 1988.
36. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74:106-120. (Pubitemid 38085242)
37. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96:434-442. (Pubitemid 38443646)
38. Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 2007; 27:5479-5485. (Pubitemid 47124400)
39. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27:6213-6221.
40. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH,Wang D, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 108:766-772. (Pubitemid 38076410)
41. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15:6758-6762.
42. Duan J, Wainwright MS, Comeron JM, Saiton N, Sanders AR, Gelernter J, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12:205-216. (Pubitemid 36204418)
43. Jupe ER, Badgett AA, Neas BR, Craft MA, Mitchell DS, Resta R, et al. Single nucleotide polymorphism in prohibitin 39 untranslated region and breastcancer susceptibility. Lancet 2001; 357:1588-1589. (Pubitemid 32488819)
44. Knight JC. Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. Clin Sci (Lond) 2003; 104:493-501. (Pubitemid 36628145)
45. Pesole G, Mignone F, Gissi C, Grillo G, Licciulli F, Liuni S. Structural and functional features of eukaryotic mRNA untranslated regions. Gene 2001; 276:73-81. (Pubitemid 32925261)
46. Mancini F, Conza GD, Moretti F. MDM4 (MDMX) and its transcript variants. Curr Genomics 2009; 10:42-50.
47. Rallapalli R, Strachan G, Cho B, Mercer WE, Hall DJ. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J Biol Chem 1999; 274:8299-8308.
48. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61-66. (Pubitemid 44684754)
49. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999; 59:6091-6096. (Pubitemid 30035626)
50. Giglio S, Mancini F, Gentiletti F, Spareco G, Felicioni L, Barassi F, et al. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res 2005; 65:9687-9694. (Pubitemid 41541444)
51. Lucke JF. A critique of the false-positive report probability. Genet Epidemiol 2009; 33:145-150.
52. Marklund L, Hammarstedt L. Impact of HPV in oropharyngeal cancer. J Oncol 2011; 2011:509036.
53. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002; 8:3187-3192. (Pubitemid 35155029)
54. Chen X, Sturgis EM, Lei D, Dahlstrom K,Wei Q, Li G. Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res 2010; 70:7199-7208.